Anbio Biotechnology (NNNN) Registration filing summary

Company overview and business model

• Focuses on in vitro diagnostics (IVD) products for personalized and decentralized healthcare, offering solutions for OTC, point-of-care, and laboratory settings.

• Product portfolio covers infectious diseases, cancer, cardiovascular, endocrine, renal, pharmacogenomics, and diabetes diagnostics.

• Operates as a holding company with main operations in Europe via a BVI subsidiary; products are manufactured by third parties.

• All IVD products are CE marked under IVDD and ready for commercialization; expansion targets EU, APAC, Americas, and Africa.

• Business model leverages third-party R&D and manufacturing, with Anbio retaining all IP and revenue from sales.

Financial performance and metrics

• Revenue for FY 2023: $6.71M (down from $23.54M in 2022); net income for FY 2023: $2.25M (down from $10.01M in 2022).

• For the six months ended June 30, 2024: revenue $5.85M, net income $3.60M, gross margin 66.85%.

• Majority of 2022–2023 revenue from COVID-19 and respiratory products; non-COVID products now increasing in share.

• Significant customer concentration: top four customers accounted for 83% of 2023 revenue.

• Cash and cash equivalents as of June 30, 2024: $10.3M; working capital: $18.2M.

Use of proceeds and capital allocation

• Estimated net proceeds from IPO: $6.99M (at $5.00/share IPO price).

• 35% allocated to expansion of sales/distribution, 20% to R&D, 45% to working capital and general corporate purposes.

• Proceeds will not be used for regulatory filings; existing cash reserves will cover those expenses.